Coloplast Gestion

Gestion contrôle des critères 4/4

Le PDG Coloplast est Kristian Villumsen, nommé en Dec2018, a un mandat de 5.92 ans. La rémunération annuelle totale est DKK 22.00M, composée du salaire de 55.9% et des bonus 44.1%, y compris les actions et options de la société. détient directement 0.045% des actions de la société, d'une valeur de € 12.08M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.9 ans et 6.8 ans.

Informations clés

Kristian Villumsen

Directeur général

DKK 22.0m

Rémunération totale

Pourcentage du salaire du PDG	55.9%
Durée du mandat du directeur général	5.9yrs
Propriété du PDG	0.04%
Durée moyenne d'occupation des postes de direction	5.9yrs
Durée moyenne du mandat des membres du conseil d'administration	6.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Kristian Villumsen a-t-elle évolué par rapport aux bénéfices de Coloplast?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	DKK 22m	DKK 12m	DKK 5b
Jun 30 2024	n/a	n/a	DKK 5b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	n/a	n/a	DKK 5b
Sep 30 2023	DKK 23m	DKK 12m	DKK 5b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	n/a	n/a	DKK 5b
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b

Rémunération vs marché: La rémunération totale de Kristian ($USD 3.10M ) est dans la moyenne des entreprises de taille similaire sur le marché Austrian ($USD 4.29M ).

Rémunération et revenus: La rémunération de Kristian a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Kristian Villumsen (54 yo)

5.9yrs

Titularisation

DKK 22,000,000

Compensation

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Kristian Villumsen	President & CEO	5.9yrs	DKK 22.00m	0.045% € 12.1m
Anders Lonning-Skovgaard	Executive VP & CFO	10.3yrs	DKK 11.30m	0.0012% € 317.0k
Allan Rasmussen	Executive Vice President of Global Operations	10.3yrs	DKK 9.90m	0.011% € 3.0m
Nicolai Andersen	Executive Vice President of Chronic Care	no data	DKK 9.50m	pas de données
Paul Marcun	Executive Vice President of Growth	5.8yrs	DKK 11.50m	0.014% € 3.6m
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000020% € 5.4k
Aleksandra Dimovska	Vice President of Investor Relations	no data	pas de données	pas de données
Dennis Kaysen	Vice President of Corporate Communications	no data	pas de données	pas de données
Dorthe Ronnau	Executive Vice President of People & Culture	2.8yrs	pas de données	pas de données
Alain Morvan	Senior Vice President of Sales Europe	12.6yrs	pas de données	pas de données
Caroline Rosenstand	Executive Vice President of Voice & Respiratory Care	no data	pas de données	pas de données
Rasmus Møller	Senior Vice President of Wound & Skin Care	4.2yrs	pas de données	pas de données

5.9yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de COLO est chevronnée et expérimentée (5.9 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Thomas Barfod	Senior Controller & Employees Representative Director	18.8yrs	DKK 450.00k	0.000020% € 5.4k
Carsten Hellmann	Independent Director	6.9yrs	DKK 690.00k	0.0027% € 717.2k
Lars Rasmussen	Independent Chairman of the Board	5.9yrs	DKK 1.84m	0.0054% € 1.4m
Niels Louis-Hansen	Deputy Chairman	56.8yrs	DKK 938.00k	1.93% € 519.2m
Marianne Wiinholt	Independent Director	3.9yrs	DKK 880.00k	0.00022% € 59.1k
Jette Nygaard-Andersen	Independent Director	8.9yrs	DKK 600.00k	pas de données
Nikolaj Gundersen	Employees Representative Director	6.8yrs	DKK 450.00k	pas de données
Roland Pedersen	Employees Representative Director	6.8yrs	DKK 450.00k	0.00072% € 193.4k
Annette Bruls	Independent Director	2.9yrs	DKK 600.00k	pas de données

6.8yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de COLO sont considérés comme expérimentés (ancienneté moyenne 6.8 ans).

Coloplast Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Deputy Chairman recently bought €5.4m worth of stock

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Final dividend of kr.17.00 announced

Full year 2024 earnings released: EPS: kr.22.46 (vs kr.22.21 in FY 2023)

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Third quarter 2024 earnings released: EPS: kr.5.67 (vs kr.5.99 in 3Q 2023)

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

First half dividend of kr.5.00 announced

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023)

First quarter 2024 earnings released

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

New minor risk - Share price stability

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Full year 2023 earnings released

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought €5.4m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022)

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Upcoming dividend of kr.15.00 per share

Less than half of directors are independent

Coloplast Announces Executive Changes

Full year 2022 earnings released: EPS: kr.22.17 (vs kr.22.67 in FY 2021)

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Third quarter 2022 earnings released

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Second quarter 2021 earnings released

Coloplast A/S Provides Earnings for the Year 2021

New 90-day low: €116

First quarter 2021 earnings released

Revenue beats expectations

New 90-day high: €137

New 90-day low: €119

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

New 90-day low: €122

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

New 90-day low: €130

New 90-day low: €132

New 90-day low - €135

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

New 90-day low - €136

Analyse de la rémunération des PDG